As a GLP-1 receptor agonist, it enhances the secretion of insulin, the hormone responsible for regulating blood glucose levels
From the perspective of scientific research, existing recommendations for analytic procedures in real-world-study-based CEAs remain insufficient [7, 8, 51]
While the first GLP-1 was approved by the FDA more than 20 years ago, to treat Type 2 diabetes, the use of these drugs took off in 2021 when Novo Nordisk received approval for a semaglutide drug to treat obesity, with the brand name Wegovy
The genetic test also screens GIPR rs1800437 and FTO rs9939609 variants, which influence appetite regulation and metabolic response patterns
Upcoming weight loss treatments Wegovy 7.2 mg: High-dose treatment (now available) The highest approved dose of Wegovy was 2.4 mg
Bypassing safeguards For Johannesburg-based endocrinologist Professor Zaheer Bayat, these regulatory warnings are no longer theoretical abstractions